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Abstract:  Objective: To estimate the prevalence, predictors, and impact of low high-density lipoprotein cholesterol 
(HDL-C) on in-hospital outcomes among acute coronary syndrome (ACS) patients in the Middle East. 
Methods: Data were collected prospectively from 6,266 consecutive patients admitted with a diagnosis of ACS and   
enrolled in the Gulf Registry of Acute Coronary Events (Gulf RACE). A low HDL-C was defined as a level <40 mg/dL 
(1.0 mmol/L) for males and <50 mg/dL (1.3 mmol/L) for females. Analyses were performed using univariate and   
multivariate statistical techniques. 
Results: The overall mean age of the cohort was 56±12 years and majority were males (77%). The overall prevalence of 
low HDL-C was 62%. During in-hospital stay and at discharge, the majority were on statin therapy (83%) while 10% 
were on other cholesterol lowering agents. After adjustment of demographic and clinical characteristics, the predictors for 
low HDL-C were higher body mass index (BMI), prior myocardial infarction (MI), diabetes mellitus, smoking and impaired 
renal function. Multivariable adjustment revealed that low HDL-C was associated with higher in-hospital mortality (odds 
ratio (OR), 1.54; 95% CI: 1.06-2.24; p=0.022) and cardiogenic shock (OR, 1.61; 95% CI: 1.20-2.14; p=0.001). 
Conclusions: ACS patients in the Middle East have a high prevalence of low HDL-C. Higher BMI, prior MI, diabetes 
mellitus, smoking, and impaired renal function were predictors of low HDL-C. Significantly higher in-hospital mortality 
and cardiogenic shock were associated with low HDL-C in men but not in women. 
Keywords: High density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, acute coronary syndrome, 
myocardial infarction, gender, Middle East. 
INTRODUCTION 
  There is consistent epidemiological and clinical evidence 
showing low high-density lipoprotein cholesterol (HDL-C) 
to be a strong independent risk factor for coronary heart dis-
ease (CHD) [1]. There is also evidence that CHD progression  
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can be attenuated by increasing HDL-C levels [2,3]. In addition, 
low levels of HDL-C may account for a significant percentage 
of residual cardiovascular risk in patients with CHD [4-6].
 
Low HDL-C levels in patients with CHD is frequently   
associated with metabolic syndrome [7].
  Furthermore,  
the fact that there is no exact definition of optimal plasma 
HDL-C levels, a threshold of <1.05 mmol/L is likely to be 
undesirable in patients with CHD or CHD equivalents
 [8]. 
  To our knowledge, there is scant literature on the subject 
from the Gulf, with only 1 published study by our group on 204    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Al-Rasadi et al. 
the prevalence of low HDL-C in Oman
 [9]. The Gulf Regis-
try of Acute Coronary Events (Gulf RACE) is a prospective, 
multi-country, multi-centre registry of consecutive patients 
hospitalized with the final diagnosis of acute coronary syn-
drome (ACS) in 6 Arabian Gulf countries over a period of 6 
months in 2006 and 2007 [10]. This registry provided a 
unique opportunity to study the prevalence, predictors, and 
impact of low HDL-C on in-hospital outcomes among ACS 
patients in the region. 
METHODS 
  Gulf RACE design and methods have been previously 
reported
 [10]. In summary, Gulf RACE was a prospective, 
multi-national, multi-centre registry of consecutive patients 
above 18 years of age hospitalized with the final diagnosis of 
ACS from 65 hospitals in 6 Middle Eastern countries, 
namely: Oman, United Arab Emirates (UAE), Qatar, Bah-
rain, Kuwait and Yemen. A pilot phase was conducted from 
May 8, 2006 to June 6, 2006. Enrolment in the next phase of 
the registry started in January 29, 2007 and continued for 5 
months till June 29, 2007. In Oman, UAE and Yemen, most 
hospitals (covering at least 85% of the population) partici-
pated in the survey. There were no exclusion criteria. The 
diagnosis of the different types of ACS and definitions of 
data variables were based on the ACC clinical data standards
 
[11]. 
  Demographic and other baseline clinical and biochemical 
characteristics of the patients along with statin and other 
dyslipidemic therapy use were evaluated. Other dyslipidemic 
therapy included cholestyramine, colestipol, bezafibrate, 
fenofibrate, and gemfibrozil. Pre-admission medications, 
other than the use of aspirin, were not available. Current 
smoking was defined as smoking cigarettes or water-pipe 
(sheesha) within 1 month of index admission. A positive 
family history for CHD was defined as evidence of this   
disease in a parent, sibling, or children before 55 years of 
age. Low HDL–C [12,13] was defined as levels of <40 mg/dL 
(1.0 mmol/L) for men and <50 mg/dL (1.3 mmol/L) for 
women. Renal impairment was defined as serum creatinine 
clearance >2 mg/dL (177 mol/L). Institutional review board 
approval was obtained. 
Statistical Analysis 
  For categorical variables, frequencies and percentages 
were reported. Differences between groups (low HDL-C 
status, no/yes) were analyzed using Pearson’s  
2 tests (or 
Fisher’s exact tests for cells <5). For age, mean and standard 
deviation were used to summarize the data while analysis 
was performed using Student’s t-test. For the variables, body 
mass index (BMI), waist circumference, total cholesterol, 
LDL-C, and triglycerides, which were abnormally distrib-
uted, median and interquartile ranges (IQRs) were used to 
describe the data and analysis was conducted using the non-
parametric Mann-Whitney test. 
  The association between low HDL-C levels and various 
predictors was evaluated by multivariate logistic regression 
model utilizing stepwise-backwise elimination method on 
the variables on (Table 1). Furthermore, the impact of   
low HDL-C on various in-hospital outcomes (mortality,   
cardiogenic shock, re-infarction, re-ischemia, congestive 
heart failure) was also explored using multivariable logistic 
regression. Among the predictor variables used in the differ-
ent models included country, age, gender, prior aspirin   
use, smoking status, and total cholesterol. The goodness-of-
fit of the logistic models was examined using the Hosmer 
and Lemeshow goodness-of-fit statistic. Based on the 2 
distribution, a Hosmer and Lemeshow statistic with a p  > 
0.05 is considered a good fit. A 2-tailed level of significance 
was set at 0.05. Statistical analyses were conducted   
using STATA version 11.1 (STATA Corporation, College 
Station, TX). 
RESULTS 
  A total of 8,176 ACS patients were recruited from 63 
hospitals in the 6 Middle Eastern Gulf countries. The HDL-C 
levels were not available for 1,910 patients (23%). The re-
maining 6,266 patients (77%) represent the sample size for 
this study. The overall prevalence of low HDL-C was 62% 
(n=3,854), ranging from 76% in Kuwait to 43% in Yemen. 
The prevalence of low HDL-C in Oman, UAE, Qatar, and 
Bahrain was 53, 64, 66 and 59%, respectively. As shown in 
(Table 1), the mean age of the cohort was 56 ± 12 years. The 
cohort was mostly male (77%), was associated with higher 
median BMI (27 [24-30] kg/m
2) and waist circumference (95 
[86-102] cm), had a significant proportion of patients with 
hypertension (48%), diabetes (40%), smokers (39%) as well 
as prior aspirin users (39%). Most of the patients had non-
ST-elevation acute coronary syndrome (NSTE-ACS) (59%). 
The cohort was also associated with higher median total cho-
lesterol (4.7 [3.7-5.7] mmol/L) and LDL-C (3.1[2.4-4.0] 
mmol/L). Furthermore, during in-hospital stay and at dis-
charge, majority of the patients received statin therapy (83%) 
but only 10% (n=647) received other dyslipidemic therapy. 
A total of 8% of the patients (n=308/3,854) that had   
low HDL-C were neither on statin nor other dyslipidemic 
therapy. 
  The low HDL-C group, compared with the satisfactory 
HDL-C cohort, had higher rates of females (29 vs  14%; 
p<0.001), higher median BMI (27 vs 26 kg/m
2; p<0.001), 
greater waist circumference (95 vs 93 cm; p<0.001), diabetes 
(44 vs 33%; p<0.001), hypertension (51 vs 43%; p<0.001), 
prior MI (25 vs 20%; p<0.001), prior percutaneous coronary 
intervention (PCI) (12 vs 9%; p<0.001), renal impairment 
(5.6  vs  4.0%; p=0.005) and NSTE-ACS (59 vs  41%; 
p<0.001). The low HDL-C group was also associated with 
lower median total cholesterol (4.5 vs 5.0 mmol/L; p<0.001), 
LDL-C (3.1 vs  3.3 mmol/L; p<0.001) as well as higher   
median triglyceride levels (1.6 vs 1.5 mmol/L; p=0.049). 
  Adjusting for other factors in the model, the stepwise 
logistic regression (Table 2) demonstrated that ACS patients 
in UAE, Qatar, Bahrain and Kuwait were more likely while 
those in Yemen were less likely to have low HDL-C when 
compared with those patients from Oman. The model also 
demonstrated that patients with higher BMI, prior MI, diabe-
tes mellitus, smokers, and renal impairment were more likely 
to have low HDL-C. However, those that were old, male, 
and had higher LDL-C and triglyceride levels were less 
likely to be associated with low HDL-C. 
  The impact of low HDL-C on in-hospital outcomes re-
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mortality (odds ratio (OR), 1.54; 95% CI: 1.06-2.24; 
p=0.022) and cardiogenic shock (OR, 1.61; 95% CI: 1.20-
2.14; p=0.001), compared with the satisfactory HDL-C 
group. The impact of low HDL-C on other in-hospital out-
comes (re-infarction, re-ischemia, congestive heart failure) 
was not significant (Table 3). Of interest, after gender   
stratification, the impact of low HDL-C on in-hospital   
mortality and cardiogenic shock was demonstrated in males 
and not in females. 
DISCUSSION 
  This study, in 6 Gulf Middle Eastern countries, demon-
strated that a high prevalence of low HDL-C existed in   
patients presenting with ACS in the region. Patients   
with higher BMI, MI, diabetes mellitus, smoking, and renal 
impairment were more likely to have low HDL-C. However, 
those that were old, male, and had higher LDL-C and 
triglyceride levels were less likely to have low HDL-C. In 
addition, low HDL-C was associated with higher in-hospital 
mortality and cardiogenic shock. Furthermore, the study   
revealed that during in-hospital stay and at discharge, the 
majority of the patients received statin therapy while very 
few patients were taking other lipid lowering drugs.  
  In our study, the prevalence (62%) of low HDL-C in 
ACS patients was the highest among other reported studies on 
ACS which ranged from 28 to 57% (Table 4). One possible 
explanation could be attributed to the high prevalence   
of metabolic syndrome in the general population in the   
Gulf states,
 which is 10-15% higher than in most developed 
countries [14]. In addition, a high prevalence of metabolic 
syndrome [7] and obesity [15] in ACS in this region has also 
been reported. 
Table 1.  Demographic, Clinical, and Lipid Characteristics of Study Population Stratified by Level of High Density Lipoprotein 
Cholesterol (HDL-C) 
Characteristic  
Unless Specified Otherwise 
Satisfactory HDL-C 
(n=2,412) 
Low HDL-C* 
(n=3,854) 
P 
Mean age ± SD (years)  56±12  55±12  0.002 
Male gender  2,063 (86%)  2,744 (71%)  <0.001 
Family history of CAD  329 (14%)  580 (15%)  0.122 
BMI, median (IQR), kg/m
2  26 (24-29)  27 (24-30)  <0.001 
Waist circumference, median (IQR), cm  93 (84-100)  95 (88-103)  <0.001 
Diabetes mellitus  805 (33%)  1,696 (44%)  <0.001 
Hypertension  1,049 (43%)  1,975 (51%)  <0.001 
Smoking (including sheesha)  952 (39%)  1,478 (38%)  0.380 
Prior aspirin use  876 (36%)  1,598 (41%)  <0.001 
Past myocardial infarction  477 (20%)  964 (25%)  <0.001 
Past PCI  206 (9%)  476 (12%)  <0.001 
Past CABG  117 (4.9%)  224 (5.8%)  0.102 
Stroke  94 (3.9%)  177 (4.6%)  0.188 
Renal impairment**  93 (4.0%)  211 (5.6%)  0.005 
Killip 3  206 (8.5%)  309 (8.0%)  0.478 
NSTE-ACS  1,298 (54%)  2,411 (63%) 
STEMI  1,114 (46%)  1,443 (37%) 
<0.001 
Total cholesterol, median (IQR), mmol/l  5.0 (3.8-6.1)  4.5 (3.6-5.4)  <0.001 
LDL-C, median (IQR), mmol/l  3.3 (2.6-4.3)  3.1 (2.4-3.9)  <0.001 
Triglyceride, median (IQR), mmol/l  1.5 (1.0-2.5)  1.6 (1.1-2.3)  0.049 
Initiation of Statin in-hospital  2,040 (85%)  3,147 (82%)  0.003 
Initiation of Other lipid lowering therapy in-hospital  174 (7.2%)  473 (12%)  <0.001 
SD = Standard deviation; CAD = Coronary artery disease; BMI = Body mass index; IQR = Interquartile range; PCI = Percutaneous coronary intervention; CABG = Coronary artery 
bypass graft surgery; *Low HDL-C was defined as a level <40 mg/dL (1.0 mmol/L) for males and <50 mg/dL (1.3 mmol/L) for females. **Defined as serum creatinine >177 mol/L 
(2 mg/dL); NSTE-ACS = Non-ST-segment elevation acute coronary syndrome; STEMI = ST-segment elevation myocardial infarction.  
Analyses were conducted using chi-square test, Student’s t-test, or Wilcoxon-Mann Whitney test, whenever appropriate. 206    The Open Cardiovascular Medicine Journal, 2011, Volume 5  Al-Rasadi et al. 
Table 2.  Predictors of Low High Density Lipoprotein Choles-
terol (HDL-C) Among the Study Cohort Utilizing 
Step-Wise Back-Wise Multivariable Logistic   
Regression 
Parameter  Odds Ratio  95% CI  P 
Oman (n = 1,458)  Ref  Ref  Ref 
UAE (n = 1,369)  2.36  1.97-2.83  <0.001 
Qatar (n = 392)  2.28  1.76-2.96  <0.001 
Bahrain (n = 197)  1.45  1.02-2.04  0.036 
Kuwait (n = 1,847)  3.38  2.84-4.03  <0.001 
Yemen (n = 1,003)  0.90  0.74-1.08  0.254 
Age 0.99  0.99-0.99  <0.001 
Male 0.30  0.26-0.36  <0.001 
Body mass index  1.02  1.01-1.04  <0.001 
LDL-C 0.86  0.82-0.90  <0.001 
Myocardial infarction  1.17  1.01-1.36  0.035 
Diabetes mellitus  1.20  1.06-1.36  0.005 
Triglycerides 0.95  0.92-0.98  0.001 
Smoking 1.21  1.06-1.38  0.006 
Renal impairment*  1.56  1.16-2.09  0.003 
CI = Confidence interval; UAE = United Arab Emirates; LDL-C = Low-density lipo-
protein cholesterol; Renal impairment* = serum creatinine >177 mol/L (2 mg/dL);  
The variables that were dropped out of the multivariable logistic regression utilizing 
stepwise-backwise elimination method included family history of coronary artery 
disease, waist circumference, coronary artery bypass graft, myocardial infarction, statin 
use, fibrate/niacin use, ST-elevation myocardial infarction; percutaneous coronary 
intervention, Killip class score; prior aspirin use, diabetes mellitus and stroke. 
The logistic model is statistically significant (LR 
2(14) = 797; p<0.001). The Hosmer-
Lemeshow chi-square statistic (a measure of the goodness-of-fit) was 10.3 and the   
p value was 0.244 denoting good model fit. 
Table  3.  Impact of Low High-Density Lipoprotein Choles-
terol (HDL-C) on in-Hospital Outcomes Among 
Acute Coronary Syndrome Patients in the Middle East 
In-Hospital Outcome  Odds Ratio  95% CI  P 
Recurrent ischemia  1.17  0.96-1.41  0.112 
Congestive heart failure  1.05  0.90-1,22  0.509 
Reinfarction 0.90  0.64-1.29  0.573 
Cardiogenic shock  1.61  1.20-2.14  0.001 
Mortality 1.54  1.06-2.24  0.022 
CI = Confidence interval; The different covariates in the adjusted multivariable logistic 
regression models included age, gender, prior aspirin use, smoking, and total cholesterol; 
all the adjusted models were statistically significant (P<0.001); The models also fit 
reasonably well (the P values for the Hosmer and Lemeshow statistics were all >.05). 
 
  Low HDL-C is a component of metabolic syndrome   
and seen more commonly with obesity and diabetes [16,17]. 
In our analysis, patients with higher BMI, and diabetes mel-
litus, were more likely to have low HDL-C even after adjust-
ing for other factors. Diabetic patients who have low HDL-C 
levels have cardiovascular event rates greater than those of 
diabetic patients with normal HDL-C levels [18,19]. There  
is high prevalence of obesity among the Gulf countries. A 
previous published report from Gulf RACE revealed that an 
overall 67% of patients with ACS were overweight or obese 
and were more likely to be female and have diabetes mellitus. 
[15]
  Kato and colleagues [20], showed that among the   
components of metabolic syndrome, abdominal obesity   
and low HDL-C levels were more frequently observed in 
patients with multiple, complex coronary lesions. Therefore, 
abdominal obesity and low HDL-C are likely to be key factors 
for coronary plaque vulnerability and may be associated with 
the poor clinical outcomes of ACS patients. Low HDL-C 
appears to be potentially a modifiable risk factor for patients 
Table 4.  Prevalence and Impact of Low High-Density Lipoprotein Cholesterol (HDL-C) on Cardiovascular Outcomes in Hospital-
ized Patients with Acute Coronary Syndrome 
Author  Country  N  Low HDL-C  Outcomes (Low HDL-C vs Satisfactory HDL-C) 
Sachdeva et al. [25]  USA 136,905  55%    n/a 
Roe et al. [26]  USA 93,263  53% 
 
  Significantly higher all-cause hospital mortality 
  Significantly higher risk of multi-vessel coronary disease on angiography 
Wolfram et al. [27]  USA  1,032  53%    Significant higher in-hospital mortality 
  Significant higher major adverse cardiac events 
Pintó et al. [28]  Spain 367  57%    n/a 
Arai et al. [29]  Japan 249  34%    Significantly higher incidence of target lesion revascularization 
Al-Zakwani et al. [9]  Oman 1,458  53%      Significant higher all-cause mortality (2.3 vs 0.6%; adjusted OR = 4.63; p=0.006)  
Correia et al. [30]  Brazil 97  28%    Significant higher incidence of events (death, non-fatal myocardial  
  infarction or recurrent unstable angina (33 vs 9%; OR = 3.6; p=0.05)  
Al-Rasadi et al.  
(present study) 
Middle East  6,266  62%    Significant higher all-cause mortality (2.52 vs 2.36%; adjusted OR = 1.54; p=0.022) 
  Significant higher rate of in-hospital cardiogenic shock (4.49 vs 3.61%; p=0.001) 
n/a = Not available; OR = Odds ratio. Prevalence, Predictors, and Impact of Low HDL-C in ACS  The Open Cardiovascular Medicine Journal, 2011, Volume 5    207 
with ACS. Optimization of lifestyle modifications by moder-
ate weight loss (by 5-10%) combined with exercise signifi-
cantly decrease triglycerides and increase HDL-C levels, 
consequently improving cardiovascular risk [21]. 
  Low HDL-C has been shown to be associated with a 
higher risk of cardiovascular events and a greater burden of 
atherosclerosis, even among patients with controlled LDL-C, 
including those who are treated with a high dose statins 
[22,23].
  In this context, a meta-analysis by Jafri et al., 
showed that low levels of HDL-C remain significantly and 
independently associated with increased cardiovascular risk 
despite statin treatment [24]. Several other studies [9,25-31]
 
including, our study (Table 3) have reported an association 
between low HDL-C and higher in-hospital or short-term 
mortality and adverse cardiac events. In the Can Rapid 
Stratification of Unstable Angina Patients Suppress Adverse 
Outcomes with Early Implementation of the American Col-
lege of Cardiology (ACC)/American Heart Association 
(AHA) Guideline (CRUSADE) trial [26],
  around 53% of 
patients admitted with NSTE-ACS had low HDL-C (<1.0 
mmol/L). In this study low HDL-C was independently asso-
ciated with an increased likelihood of severe coronary dis-
ease and in-hospital mortality. Moreover, a study by Correia 
et al., [30]
 demonstrated that low levels of HDL-C at admis-
sion in individuals with non-ST-elevation ACS predicted 
recurrent in-hospital events during hospitalization and LDL-
C and triglycerides were not associated with cardiovascular 
events. Similarly, analysis from the Myocardial Ischemia 
Reduction with Aggressive Cholesterol Lowering (MIRACL) 
trial [31], showed that despite aggressive lipid lowering with 
80 mg of atorvastatin, HDL-C, but not LDL-C influenced 
short-term prognosis in patients after ACS. Furthermore, in 
the Japan Assessment of Pitavastatin and Atorvastatin in 
Acute Coronary Syndrome (JAPAN-ACS) [29],
 patients with 
low HDL-C had a significantly higher incidence of target 
lesion revascularization.
 
  The actual rate of cardiogenic shock in patients with low 
HDL-C is poorly defined. In the current study, low HDL-C 
was an independent predictor of cardiogenic shock among 
ACS patients. Furthermore, Zeller et al., [32] showed that 
hyperglycemia and low HDL-C levels had the strongest as-
sociation with severe heart failure and only hyperglycemia 
was an independent determinant of cardiogenic shock. Since 
this study is the only published to date, further studies are 
needed to corroborate this new possible association between 
low HDL-C and cardiogenic shock. 
  This study, compared to our previous published study   
on prevalence of low HDL-C from Oman [9], has looked 
more into the impact of low HDL-C on in-hospital outcomes 
after gender stratification because the population is greater  
(n = 6,266 vs 1,458) and consequently more powered to   
detect differences on the impact of low HDL-C on in-
hospital outcomes than the Oman [9] study. In the current 
study (n = 6,266), women had a higher prevalence of low 
HDL-C compared with men (76 vs 57%; p<0.001) despite of 
no significant differences of in-hospital dyslipidemic therapy 
other statins, such as fibric acid, nicotinic acid, etc (1.2 vs 
0.9%; p=0.473). This is likely related to the high prevalence 
of obesity and metabolic syndrome among women in the 
Gulf countries [7,15].
  Similarly a published Gulf RACE 
study on gender differences showed that women had higher 
rates of other cardiovascular risk factors such as diabetes and 
hypertension [33]. Moreover in their study, women had 
higher adjusted in-hospital mortality compared with men. 
However, in our study, low HDL-C did not correlate with 
either mortality or cardiogenic shock in women and it is only 
in men that low HDL-C  was significantly related to both 
mortality and cardiogenic shock.  
  The clinical benefit of aggressive lowering of LDL-C 
among patients with ACS has been strongly demonstrated 
and has been translated into clinical practice [34,35].
  Al-
though, the current Adult Treatment Panel III (ATP III) 
guidelines recommend treatment of low HDL-C [36], in-
creasing HDL-C levels among patients with ACS have ap-
parently been poorly translated into clinical practice. This is 
further demonstrated in our study, which showed that only 
473 out of 3,854 patients (12%) with low HDL-C levels 
were discharged on a combination therapy to increase HDL-
C levels. Likely reasons for the observed under treatment in 
patients with low HDL-C include underestimation of therapy 
benefit, lack of prospective clinical trial data, and under-
recognition of patients’ poor prognosis. 
  Strategies to aggressive management of HDLC are fun-
damental for reducing cardiovascular outcomes in patients 
with ACS. Nissen et al., [37],
 reported a significant decrease 
in atheroma in patients with ACS who were treated with in-
fusions containing apolipoprotein A-I Milano compared with 
placebo. The HDL-C Atherosclerosis Treatment Study 
(HATS) [38] showed that combining nicotinic acid with a 
statin improved HDL-C and LDL-C, inhibited the progres-
sion of atherosclerosis, and reduced cardiovascular event 
rates in a high-risk population with established CHD. Re-
cently, Taylor and colleagues [39] have shown that the use 
of extended-release niacin causes significant regression of 
carotid intima media thickness when combined with statins. 
  One difficulty with HDL-C elevating therapy at present, 
is that there is no exact definition of the optimal plasma 
HDL-C level, although there is a consensus that <1.05 
mmol/L is undesirable in patients with CHD or CHD equiva-
lents [8].
 Furthermore, the recent 2009 Canadian guidelines 
for the diagnosis and treatment of dyslipidemia do not spec-
ify treatment targets for HDL-C in high risk patients [40].
. 
However, published studies to raise plasma HDL-C had 
shown that beneficial effects of HDL-C are likely not related 
simply to its abundance. Atherothrombosis Intervention in 
Metabolic Syndrome with Low HDL-C/High Triglyceride 
and Impact on Global Health Outcomes (AIM-HIGH) was 
recently discontinued [41]. The trial showed that adding ex-
tended-release niacin to statin therapy in people with estab-
lished vascular disease and despite increasing plasma HDL-
C it did not reduce the risk of cardiovascular events. These 
findings are preliminary and require full evaluation to look at 
specific reasons for the failure. Moreover, a meta-analysis by 
Briel et al., showed no association between changes in levels 
of HDL-C and reducing the risk of coronary heart disease 
events, coronary heart disease deaths or total deaths [42].
 
There is evidence that HDL-C functional assays, like choles-
terol efflux study, paraoxonase 1 (PON1) activity, antioxi-
dant and anti-inflammatory properties are better predictor of 
cardiac events than plasma HDL-C [43].
  Studies had re-
vealed that these HDL-C properties are impaired in patients 
with CHD compared with control healthy individuals [44].
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Landmesser, and his research team recently showed that 
HDL-C of patients with either ACS or stable CAD compared 
to HDL-C from healthy individuals fail to stimulate endothe-
lial nitric oxide (eNOS) activating pathways and nitric oxide 
(NO) production. As a result, the endothelial anti-
inflammatory and endothelial repair effects of HDL are im-
paired [43]. 
Study Limitations 
  The limitations of a registry-type study apply, such as 
unidentified confounders which could influence the results. 
Furthermore, lipid levels may be partially affected during   
the acute phase of ACS and this could have influenced the 
estimation of low HDL-C levels [45].
  However, a recent 
study found little change in lipid levels measured serially in 
the first days of hospitalization for ACS [46].
  Treatment 
(with lipid lowering drugs or other medication) may also 
affect lipid levels and their interrelationships 
CONCLUSIONS 
  This study demonstrated a high prevalence of low HDL-
C levels in ACS patients in the Middle East and that this 
abnormality was more common in females than in males. 
BMI and diabetes were independent predictors for low HDL-
C. Low HDL-C was associated with in-hospital mortality 
and cardiogenic shock in men but not in women. Although 
guidelines for LDL-C management in ACS are well   
established, treatment recommendations concerning HDL-C 
levels are not as rigorous or aggressive. Failure to recognize 
the prognostic value of low HDL-C in ACS may predispose 
these patients to higher risk of recurrent events and worse 
outcomes. 
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